ALK and non-small cell lung carcinoma: The objective of this analysis was to externally validate the TGI-OS model based on unselected or PD-L1 selected NSCLC patients included in atezolizumab trials to predict treatment effect (HR) in a biomarker-selected (ALK-positive) population included in alectinib ALEX trial.